The firm closed an oversubscribed Series B financing round to fund a pivotal trial of RTx-015 and advance a clinical trial in ...
Regulators reviewed data from the Phase II FIREFLY-1 trial, in which the overall response rate was 53 percent, according to a scale for low-grade gliomas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results